高迁移率族蛋白A1在肿瘤发生发展中的作用

doi:10.3760/cma.j.issn.1673-422X.2014.01.005

摘要/Abstract

摘要： 高迁移率族蛋白A1（HMGA1）是一种非组蛋白的染色质相关蛋白，可以通过多种途径对肿瘤相关基因进行转录调控，进而影响肿瘤的发生发展。HMGA1不仅可以作为肿瘤的标志物，而且还可作为肿瘤的预后指标和治疗靶点，为肿瘤生物治疗提供了新途径。

关键词: HMGA蛋白质类, 肿瘤, 转录, 预后

Abstract: High mobility group protein A1 (HMGA1), one of the nonhistone chromatin proteins, can regulate the transcription of several tumor related genes by various different ways, thereby effecting the formation and growth of tumor. So HMGA1 can be not only used as a tumor marker, but also as indicator of tumor prognosis and therapeutic target, and then providing new ways for the tumor biological therapies.

Key words: HMGA proteins, Neoplasms, Transcription, Prognosis

王运良, 李翠, 贾喜花等. 高迁移率族蛋白A1在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2014, 41(1): 14-17.

WANG Yun-Liang, LI Cui, JIA Xi-Hua, et al. Role of high mobility group protein A1 in tumor development[J]. Journal of International Oncology, 2014, 41(1): 14-17.

参考文献

［1］ Shah SN, Resar LM. High mobility group A1 and cancer: potential biomarker and therapeutic target［J］. Histol Histopathol, 2012, 27(5):567579. ［2］ Fedele M, Visone R, De Martino I, et al. Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and Bcell lymphomas in mice［J］. Eur J Cancer, 2011, 47(3):470478. ［3］ Resar LM. The high mobility group A1 gene: transforming inflammatory signals into cancer? ［J］. Cancer Res, 2010, 70(2):436439. ［4］ Rho YS, Lim YC, Park IS, et al. High mobility group HMGI (Y) protein expression in head and neck squamous cell carcinoma［J］. Acta Otolaryngol, 2007, 127(1):7681. ［5］ Zhang Y, Ma T, Yang S, et al. Highmobility group A1 proteins enhance the expression of the oncogenic miR222 in lung cancer cells［J］. Mol Cell Biochem, 2011, 357(12):363371. ［6］ Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells［J］. PLoS One, 2012, 7(1):3034. ［7］ Cleynen I, Huysmans C, Sasazuki T, et al. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Rasregulated expression［J］. Cancer Res, 2007, 67(10):46204629. ［8］ Ha TK, Her NG, Lee MG, et al. Caveolin1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1mediated GLUT3 transcription［J］. Cancer Res, 2012, 72(16):40974109. ［9］ Fedele M, Fusco A. Role of the high mobility group A proteins in the regulation of pituitary cell cycle［J］. J Mol Endocrinol, 2010, 44(6):309318. ［10］ De Martino I, Visone R, Wierinckx A ,et al. HMGA proteins upregulate CCNB2 gene in mouse and human pituitary adenomas［J］. Cancer Res, 2009, 69(5):18441850. ［11］ Palmieri D, Valentino T, D′Angelo D, et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents ［J］. Oncogene, 2011, 30(27):30243035. ［12］ Xu M, Sharma P, Pan S, et al. Core promoterselective function of HMGA1 and mediator in initiatordependent transcription［J］. Genes Dev, 2011, 25(23):25132524. ［13］ Mao L, Wertzler KJ, Maloney SC, et al. HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency［J］. Mol Cell Biol, 2009, 29(20):54265440. ［14］ Maloney SC, Adair JE, Smerdon MJ, et al. Genespecific nucleotide excision repair is impaired in human cells expressing elevated levels of high mobility group A1 nonhistone proteins［J］. DNA Repair(Amst), 2007, 6(9):13711379. ［15］ Bloch M, Prock A, Paonessa F, et al. Highmobility group A1 protein: a new coregulator of peroxisome proliferatoractivated receptor γmediated transrepression in the vasculature［J］. Circ Res, 2012, 110 (3):394405. ［16］ De Martino I, Visone R, Fedele M, et al. Regulation of microRNA expression by HMGA1 proteins［J］. Oncogene, 2009, 28(11):14321442. ［17］ Liu Y, Wang Y, Zhang Y, et al. Knockdown of HMGA1 expression by short/small hairpin RNA inhibits growth of ovarian carcinoma cells［J］. Biotechnol Appl Biochem, 2012 , 59(1):15. ［18］ Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells［J］. PLoS One, 2012, 7(1):e30034. ［19］ Schuldenfrei A, Belton A, Kowalski J, et al. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis［J］. BMC Genomics, 2011, 12:549556. ［20］ Akaboshi S, Watanabe S, Hino Y, et al. HMGA1 is induced by Wnt/betacatenin pathway and maintains cell proliferation in gastric cancer［J］. Am J Pathol, 2009, 175 (4):16751685. ［21］ Hillion J, Smail SS, Di Cello F, et al. The HMGA1COX2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma［J］. Pancreatology, 2012, 12 (4):372379. ［22］ Esposito F, Tornincasa M, Federico A, et al. Highmobility group A1 protein inhibits p53mediated intrinsic apoptosis by interacting with Bcl2 at mitochondria［J］. Cell Death Dis, 2012, 30(3):e383. ［23］ Takaha N, Sowa Y, Takeuchi I, et al. Expression and role of HMGA1 in renal cell carcinoma［J］. J Urol, 2012, 187(6):22152222. ［24］ Esposito F, Tornincasa M, Chieffi P, et al. Highmobility group A1 proteins regulate p53mediated transcription of Bcl2 gene［J］. Cancer Res, 2010, 70(13):53795388. ［25］ Hillion J, Wood LJ, Mukherjee M, et al. Upregulation of MMP2 by HMGA1 promotes transformation in undifferentiated, largecell lung cancer［J］. Mol Cancer Res, 2009, 7(11):18031812. ［26］ Takeuchi I, Takaha N, Nakamura T, et al. High mobility group protein AThook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells［J］. Prostate, 2012, 72 (10):11241132. ［27］ Aiello A, Pandini G, Sarfstein R, et al. HMGA1 protein is a positive regulator of the insulinlike growth factorI receptor gene［J］. Eur J Cancer, 2010, 46(10):19191926.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.